Ginkgo Bioworks shares surge 10.82% premarket after OpenAI collaboration cuts protein synthesis costs by 40%.

Ginkgo Bioworks surged 10.82% in premarket trading following the announcement of a collaboration with OpenAI that demonstrated a GPT-5-driven autonomous lab reducing cell-free protein synthesis costs by 40%. The system executed 36,000 experiments across six cycles, achieving $422 per gram of protein compared to the prior $698 benchmark, while generating 150,000 data points with minimal human oversight. The company began selling the AI-optimized reagent mix and released the Pydantic validation model as open source, signaling commercial scalability and technological advancement. Reshma Shetty highlighted the cost efficiency enabling "more scientific progress per dollar spent," underscoring the innovation's market potential. The breakthrough validates Ginkgo’s cloud lab capabilities and aligns with broader AI integration in biotechnology, driving investor optimism.